linjc16/ctgov huggingface dataset:
UGT1A1 Genotyping in Taiwanese Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Irinotecan is commonly used to treat lung, colorectal, pancreatic, stomach, esophageal, and other types of cancer. The main metabolic pathway of SN-38, the active product of Irinotecan, is grape glycoalkaloid acidification by UDP - glucuronosyltransferase (UGT1A1) and then excreted through bile and urine. Clinically, Irinotecan treatment can cause many adverse reactions, and differences in UGT1A1 genotypes can lead to structural changes or functional defects in enzymes, causing reduced acidification of grape glycolaldehyde, and increasing Irinotecan side effects. Therefore, if the patient's ability to metabolize the drug can be assessed before taking the drug, it will be of great help in treatment. Until 2021, cancer will remain the top ten causes of death in Taiwan, of which colorectal and pancreatic cancer rank third and seventh among the top ten cancers in Taiwan, respectively, and these two cancers often use complex chemotherapy including irinotecan. Routine detection of UGT1A1 genotype in patients with colorectal and pancreatic cancer before irinotecan treatment predicts the drug metabolism capacity of irinotecan and adjusts the dose, allowing patients receiving irinotecan to reduce the harm of side effects. At present, the UGT1A1 genotype evaluated is usually only UGT1A1*28, but the common UGT1A1 genotype in Taiwan also has UGT1A1*6 and UG1A1*63, etc. There is no literature on Taiwanese cancer patients with actual irinotecan chemotherapy, so this study aims to explore the influence of the UGT1A1 genotype and develop other UGT1A1 genotype test methods. It is expected that molecular testing tools can improve cancer precision medicine and provide personalized medicine.

Official Title
-----------------
Impact of Routine UGT1A1 Genotyping Before Irinotecan Chemotherapy in Taiwanese Cancer Patients

Conditions
-----------------
The Influence of the UGT1A1 Genotype

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colorectal or pancreatic cancer patients. Exclusion Criteria: Age less than 20 or greater than 90.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Using Sanger sequencing and real-time polymerase chain reaction analysis to study the distribution of UGT1A1 gene in cancer patients in Taiwan. | After Sanger sequencing and qPCR analysis, we classify several common types, such as UGT1A1*28, UGT1A1*6, and UGT1A1*63. Additionally, we aim to identify whether there are any other mutation points. | One month after receiving the samples. |
Discovering Factors in the Clinical Trial Journey of Dementia Patients

Study Overview
=================
Brief Summary
-----------------
This research aims to collect comprehensive data on the clinical trial experience of dementia patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully. Clinical trial participation often favors specific demographic groups, and limited research exists on the impact of trial attributes on participation. Therefore, this study aims to analyze data from various demographic groups and identify any recurring trends that could provide valuable insights for future dementia patients.

Official Title
-----------------
Dementia Clinical Trials: A Study on the Clinical Trial Participation of Dementia Patients

Conditions
-----------------
Dementia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. Participant has a diagnosis of dementia. Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. Exclusion Criteria: Pregnant or lactating woman Enrolled in another research study Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a dementia clinical study. |  | 3 months | 
| Number of dementia patients who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dementia
PET-CT Predicting Segement Specific Lymph Nodes Metastasis

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter prospective clinical study that aims to evaluate the predictive value of preoperative PET-CT results (such as SUV uptake, size of tumor lymph nodes, and differences in FDG uptake compared to surrounding tissues) for lymph node metastasis in patients with non-small cell lung cancer. During surgery, all patients underwent systematic mediastinal lymph node dissection. The final pathological results were used to assess the predictive value of PET-CT for segment-specific lymph node metastasis.

Official Title
-----------------
The Value of PET-CT in Predicting Segement Specific Lymph Nodes Metastasis in Non Small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion. Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1. No enlarged mediastinal lymph nodes observed on preoperative contrast-enhanced CT. Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery. Systematic lymph node dissection performed during surgery. No prior radiotherapy or chemotherapy for initial treatment. No history of malignant tumors. Exclusion Criteria: Locally advanced or distant metastasis. Pleural dissemination observed during surgery. History of malignant tumors. Received neoadjuvant therapy. Systematic lymph node dissection not performed during surgery. Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive value of PET-CT for segment-specific lymph node metastasis |  | Preoperative |
Discovering Factors in Narcolepsy Patients' Clinical Research Experiences

Study Overview
=================
Brief Summary
-----------------
An observational trial can provide a platform for patients to share experiences and perspectives on living with narcolepsy, which can inform the development of new treatments and support programs. Overall, an observational clinical trial is an important tool for advancing the understanding of narcolepsy and improving outcomes for patients.

Official Title
-----------------
The Patient Voice in Narcolepsy Clinical Trials: Reflections on Experiences and Outcomes

Conditions
-----------------
Narcolepsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 18 years of age Patient is able and willing to comply with the treatment/follow-up schedule and requirements Patient must provide written informed consent Exclusion Criteria: Women who are pregnant, intend to become pregnant, or are lactating Inability to perform regular electronic reporting Participants who are vulnerable to any intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a narcolepsy clinical study. |  | 3 months | 
| Number of narcolepsy study participants who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Narcolepsy
Blood Characteristics and Abdominal Emergency Surgery

Study Overview
=================
Brief Summary
-----------------
After surgical tissue damage, cellular blood components are involved in tissue repair processes, yet their preoperative characteristics are not considered in routine clinical practice.

Detailed Description
-----------------
Surgical injuries initiate the recruitment of cellular blood components for tissue repair. Baseline inflammation levels and cellular response to tissue damage are absent from perioperative management algorithms despite their importance in regeneration. This project seeks to examine patients preoperative parameters before surgery and evaluate if there is a correlation with clinical outcomes.

Official Title
-----------------
Association Between Preoperative Blood Characteristics and Mortality in Abdominal Emergency Surgeries

Conditions
-----------------
Surgical Wound

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a) Patients between 18 and 65 years of age at the time of surgery. b) Patients with acute intra-abdominal pathology requiring emergency surgery. c) Complete blood count performed in the emergency department of our center within the 24 hours prior to surgery. Exclusion Criteria: a) Patients who are users of anticoagulation prior to admission for any reason; b) Patients who have had previous hospitalization or surgery in the last 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| High Neutrophil count<br>Patients with high neutrophil count in their preoperative complete blood count | |
| Low Neutrophil count<br>Patients with low neutrophil count in their preoperative complete blood count | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | The number of deceased patients. | 1 year |
Effect of Sulthiame on EEG in Childhood Epilepsy Syndromes

Study Overview
=================
Brief Summary
-----------------
The effect of sulthiame on EEG has been studied in epilepsy syndromes of childhood with sleep activation by comparing sleep EEG obtained at baseline and after 4 weeks of treatment. The aim of the study is to know if an effect is still identifiable after 2 weeks of treatment by performing sleep EEG recordings after 2 and 4 weeks of treatment, respectively.

Official Title
-----------------
Treatment of Epilepsy Syndromes of Childhood With Sleep Activation Using Sulthiame: an Exploratory Study of the Short Term Effect on EEG

Conditions
-----------------
Importance of Interictal Epileptiform Activity on Sleep EEG

Intervention / Treatment
-----------------
* Drug: Sulthiame


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of epilepsy syndromes of childhood with sleep activation Failure of at least two anti-epileptic drugs (AED) Sleep EEG performed in the last 7 days before inclusion and showing interictal epileptiform discharges (baseline EEG) Exclusion Criteria: Previous trial with sulthiame More than 2 AED at inclusion Use of corticosteroids at inclusion Change in the anti-epileptic treatment in the 7 days before baseline EEG

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sulthiame|Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients showing improved sleep EEG at day 14 compared to baseline EEG |  | 14 days |
The Prevalence of Fibromyalgia in Adults at Al-Karak Jordan a Cross-sectional Study

Study Overview
=================
Brief Summary
-----------------
Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. This cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in Al-Karak, Jordan. The city's unique demographic and environmental characteristics may influence the occurrence of fibromyalgia among its adult population. The study aims to address gaps in knowledge, provide localized insights, and shed light on fibromyalgia's burden on the community's health. Accurate prevalence data aids healthcare planning and resource allocation.

Official Title
-----------------
The Prevalence of Fibromyalgia in Adults at Al-Karak Jordan a Cross-sectional Study

Conditions
-----------------
Fibromyalgia, Orthopedic Disorder

Intervention / Treatment
-----------------
* Other: Cross sectional


Participation Criteria
=================
Eligibility Criteria
-----------------
Using google forms, this cross-sectional study was carried out, and the participants were reached via social media platforms (5) . Participants' autonomy was maintained, and no direct benefit was gained in return for filling out the questionnaire. The ethics committee at the Faculty of Medicine, Mutah University, Karak, Jordan, provided the required ethical approval prior to the initiation of this study. Moreover, the committee ensured that the study was designed according to the principles of the Declaration of Helsinki (Date: 13 February 2023. Reference number: 992023). In this study, the authors targeted Karak government citizens, in Jordan. Accordingly, the required sample size to achieve a 99% Confidence interval was 663 participants.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Positive for fibromyalgia<br>26.5% prevalence of fibromyalgia | |
| Negative for fibromyalgia<br>26.5% prevalence of fibromyalgia | Other: Cross sectional<br>* Cross sectional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cross sectional | Outcome measurements | 2 years |
Endosonograpic Monitoring of Injury to the Anal Sphincter After Transanal Stapled Anastomosis

Study Overview
=================
Brief Summary
-----------------
Investigation of the sphincter muscles after low anterior or anterior rectum resection, and sigma resection operation by endoluminal ultrasound and manometrical examination.

Official Title
-----------------
Endosonograpic Monitoring of Injury to the Anal Sphincter After Transanal Stapled Anastomosis

Conditions
-----------------
Transanal Stapled Anastomosis

Intervention / Treatment
-----------------
* Device: Transanal stapling device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 90 years, undergoing transanal stapled anastomosis at the Department of General Surgery, Medical University of Vienna Ability and willingness to understand and comply with study interventions and restrictions. Voluntarily signed informed consent after full explanation of the study to the participant. Exclusion Criteria: Any physical or mental disorder, which could interfere with the participant's safety during the clinical trial or with the study objectives Inability to communicate well with the investigator due to language problems or reduced mental development Inability or unwillingness to give written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EAUS | Change in thickness of the anal sphincter muscles in mm from baseline to 3 months | 3 months postoperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endoanal manometry | Change in Anal pressure in mmHg from baseline to 3 months | 3 months postoperative | 
| EAUS2 | Change in the defect grade of anal sphincter muscles from baseline to 3 months | 3 months postoperative | 
| EAUS2-2 | Change in thickness of the anal sphincter muscles in mm from baseline to 12 months | 12 months postoperative | 
| EAUS2-2 | Change in the defect grade of anal sphincter muscles from baseline to 12 months | 12 months postoperative | 
| Endoanal manometry2 | Change in Anal pressure in mmHg from baseline to 12 months | 12 months postoperative |
Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns

Study Overview
=================
Brief Summary
-----------------
Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Merkel cell carcinoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Merkel cell carcinoma patients.

Official Title
-----------------
Merkel Cell Carcinoma Clinical Trials: What Are Prevailing Patient Experiences in Merkel Cell Carcinoma Studies

Conditions
-----------------
Merkel Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old Able to comprehend the investigational nature of the protocol and provide informed consent Diagnosis of Merkel cell carcinoma Exclusion Criteria: No diagnosis of Merkel cell carcinoma confirmed Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a Merkel cell carcinoma clinical research |  | 3 months | 
| Rate of patients who remain in Merkel cell carcinoma clinical research to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Merkel Cell Carcinoma
Central Apnoea Monitor Study

Study Overview
=================
Brief Summary
-----------------
An initial small study on 15 children that are already being investigated for central sleep apnoea in the sleep unit at Sheffield Children's Hospital. The central apnoea monitor will be placed around the child's abdomen overnight alongside the sensors already being used for the clinical sleep study and the signals from the two systems will be compared to evaluate the accuracy of the new device.

Official Title
-----------------
Feasibility Study to Evaluate a New Wearable Wireless Device for Monitoring Central Apnoeas in Infants and Children

Conditions
-----------------
Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been referred for a cardio-respiratory polygraphy sleep study. Patients aged 1 month up to 5 years old. Exclusion Criteria: Subjects whose parents/legal guardians/carers are not fluent in English, or who have special communication needs. Child anticipated to become distressed with additional sensor. Child too clinically unwell to take part (as decided by clinical staff).

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of the system in 15 patients, when compared with the gold standard measurement system |  | 24 hours | 
| The acceptability of the sensor to the child as viewed by the parent (and child) | As measured by researcher designed questionnaire | End of study |